Stay updated with breaking news from Fred Saad. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SAN FRANCISCO — The addition of olaparib to abiraterone acetate significantly extended radiographic PFS as first-line treatment for metastatic castration-resistant prostate cancer, according to an interim analysis of the randomized phase 3 PROpel study. The findings, presented at ASCO Genitourinary Cancers Symposium, showed men experienced the benefit regardless of homologous
Investegate announcements from AstraZeneca PLC, Lynparza combo delays progression risk in prostate
(RTTNews) - AstraZeneca PLC (AZN.L, AZN) Tuesday announced positive results from the PROpel Phase III trial of Lynparza (olaparib) plus abirateron...
AstraZeneca and MSD's Lynparza combo delays progression risk in prostate cancer
LONDON (dpa-AFX) - AstraZeneca PLC (AZN.L, AZN) Tuesday announced positive results from the PROpel Phase III trial of Lynparza (olaparib) plus abiraterone in 1st-line metastatic castration-resistant